Etanercept News and Research

RSS

Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.

Could arthritis wonder drugs provide clues for all disease?

Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis - a leading cause of heart disease - says the researcher who jointly invented and developed them.

From The University of Manchester 17 Jul 2008

Researchers who helped millions with arthritis receive Janssen Award

Two British researchers who pioneered treatments which have helped millions of people with rheumatoid arthritis and other autoimmune diseases have been awarded the prestigious 2008 Dr. Paul Janssen Award for Biomedical Research, announced today.

13 May 2008

Study affirms effectiveness of medication for juvenile rheumatoid arthritis

Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes.

9 May 2008

Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients

For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.

15 Apr 2008

Watery pools in bone marrow key to psoriatic arthritic damage

Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases.

4 Mar 2008

Effect of tumor necrosis factor a inhibitors on heart failure risk in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is characterized by persistent inflammation of the synovial membrane and progressive joint destruction.

28 Feb 2008

Enbrel shown to significantly reduced levels of C-reactive protein

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.

5 Feb 2008

How anti-TNF compounds work

Powerful drugs used to treat patients with rheumatoid arthritis have a profound, previously unrecognized effect on the immune system, breaking up molecular "training camps" for rogue cells that play an increasingly recognized role in autoimmune diseases like rheumatoid arthritis and lupus.

21 Jan 2008

Arthritis drug Etanercept clears up symptoms of psoriasis

New research from the United States has found that a drug commonly used to treat arthritis significantly reduces the symptoms of psoriasis in children.

20 Jan 2008

New drug lets kids feel good in their skin

Maria Anichini, a 20-year-old junior at Columbia College, zipped up a fetching black lace cocktail dress with spaghetti straps to go out with friends the other night.

17 Jan 2008

Etanercept drug reverses early symptoms of Alzheimer's in 10 minutes

Scientists in the U.S. say a drug which can reverse some of the early symptoms of Alzheimer's disease takes effect within 10 minutes.

14 Jan 2008

New study highlights importance soluble proteins, called cytokines, in Alzheimer's

An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer's disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation .

10 Jan 2008

Combining medications often best strategy to battle rheumatoid arthritis

For patients with rheumatoid arthritis, combining one well-known, lower cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report funded by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

18 Dec 2007

Combining medications often best strategy to battle rheumatoid arthritis

For patients with rheumatoid arthritis, combining one well-known, lower-cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, which is sponsored by the Agency for Healthcare Research and Quality.

19 Nov 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007

Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced the presentation of additional data that showed that the safety profile of Enbrel, (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.

17 Jun 2007